Neferine inhibits LPS-ATP-induced endothelial cell pyroptosis via regulation of ROS/NLRP3/Caspase-1 signaling pathway
- 35 Downloads
Oxidative stress-induced endothelial dysfunction and pyroptosis play an important role during chronic kidney disease (CKD) progression. Neferine, which is an alkaloid ingredient from the lotus seed embryo, has many biological actions such as anti-inflammatory, anticancer and antioxidant. However, the role of neferine in endothelial cell pyroptosis and the involved mechanism remain obscure. The aim is to probe the protective effects of neferine on cell pyroptosis and the involved underlying mechanism.
After the HUVECs were primed with neferine treatment for 2 h prior to LPS and ATP exposure for 24 h, the cell proliferation was determined by BrdU; the cell LDH release was detected by LDH kits; the levels of intracellular ROS, MDA and SOD were tested by detection kits; Caspase-1 activity kit was used to determine caspase-1 activity; the contents of NLRP3, ASC, caspase-1, IL-1β, IL-18 and GSDMD were tested by RT-PCR and western blot.
We found that neferine could inhibit LPS-ATP-induced oxidative stress and the activation of NLRP3 inflammasome signaling, and increased the endothelial cell viability and SOD production. siRNA which mediated the knockdown of NLRP3 promoted the neferine-induced inhibition effects of cell pyroptosis. Furthermore, these neferine-induced effects were reversed by the over-expression of NLRP3.
Our findings indicated neferine may reduce ROS by anti-oxidation and inhibit LPS-ATP-induced endothelial cell pyroptosis via blocking ROS/NLRP3/Caspase-1 signaling pathway, which provides the evidence for therapeutic effect in CKD.
KeywordsNeferine Cell pyroptosis NLRP3 inflammasome Chronic kidney disease (CKD) ROS/NLRP3/Caspase-1 signaling pathway
We would like to give our sincere gratitude to the reviewers for their constructive comments.
This work was supported by grants from the National Natural Science Foundation of China [no. 81470933].
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study. We would like to give our sincere gratitude to the reviewers for their constructive comments.
- 2.Madan P, Kalra OP, Agarwal S, Tandon OP. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc. 2014;36:116–7.Google Scholar
- 7.Olgaard K, Lewin E. Use (or misuse) of vitamin D treatment in CKD and dialysis patients: a recent meta-analysis on vitamin D compounds in chronic kidney disease  and an editorial comment  accompanying this meta-analysis have already been published. We believe that these. Nephrol Dial Transpl. 2008;23:1789–93.CrossRefGoogle Scholar
- 12.Chow MTC. Danger signal receptors and cancer: NLRP3 inflammasome and Toll-like receptor 3. 2013.Google Scholar
- 30.Liu XD, Li H, Wang CZ, Zhao HD, Xiao P, Nephrology DO, et al. Mechanism of neferine in antioxidant stress. China J Mod Med; 2018.Google Scholar
- 31.Yoon JS, Kim HM, Yadunandam AK, Kim NH, Jung HA, Choi JS, et al. Neferine isolated from Nelumbo nucifera enhances anti-cancer activities in Hep3B cells: molecular mechanisms of cell cycle arrest, ER stress induced apoptosis and anti-angiogenic response. Phytomedicine. 2013;20:1013–22.CrossRefGoogle Scholar